FibroBiologics, Inc. FBLG 深 沪
已收盘 05-08 16:00:00 美东时间
1.16
-0.080
-6.45%
华盛通- 最 高1.25
- 今 开1.23
- 成交量 18.97万股
- 最 低 1.13
- 昨 收 1.24
- 总市值 604.23万
- 52周最高 19.80
- 市盈率 静 --
- 换手率 3.64%
- 52周最低 1.03
- 委 比 -99.92%
- 总股本 520.89万
- 历史最高 1100.00
- 量 比 0.38
- 振 幅 9.68%
- 历史最低 1.13
- 每 手 1
- 风险率 4.62%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Maxim Group Downgrades FibroBiologics to Hold
Maxim Group analyst Michael Okunewitch downgrades FibroBiologics (NASDAQ:FBLG) from Buy to Hold.
05-04 20:54
EXCLUSIVE: FibroBiologics Targets 2026 Data Readout After Trial Progress For Diabetic Foot Ulcer Study
FibroBiologics releases CYWC628 batch for DFU trial, clears cGMP checks, prepares enrollment; interim data expected in Q3 2026.
05-04 20:16
美股大行评级 | 美国银行、摩根士丹利、JB亨特运输服务、PNC金融服务、Cheniere Energy等获多家大行上调目标价
今日重点评级关注：HC Wainwright & Co.：维持FibroBiologics"买入"评级，目标价从4美元升至8美元；摩根士丹利：维持Ultragenyx药业"超配"评级，目标价从50美元升至67美元
04-17 11:27
FBS Global Receives Non-Compliance Notice From Nasdaq
Ordinary shares will continue to trade on the Nasdaq Capital Market, and the Company's listing on such exchange is not affected by the receipt of the NoticeSINGAPORE, April 16, 2026 (GLOBE NEWSWIRE) -- FBS Global Limited
04-16 19:47
FibroBiologics Receives European Patent Titled 'De-Differentiated Fibroblast-conditioned Media For Treating Or Preventing Disc Degeneration'
https://x.com/PatentGrants/status/2044505323562783041?s=20
04-16 03:59
D. Boral Capital Downgrades FibroBiologics to Hold
D. Boral Capital analyst Jason Kolbert downgrades FibroBiologics (NASDAQ:FBLG) from Buy to Hold.
03-27 02:30
FibroBiologics shares are trading lower after the company announced it approved a 1-for-20 reverse stock split.
FibroBiologics shares are trading lower after the company announced it approved...
03-26 04:41
FibroBiologics Approves 1-For-20 Reverse Stock Split
The reverse stock split is expected to become effective at 12:01 a.m. Eastern Time on March 30, 2026, with trading on a split-adjusted basis beginning on The Nasdaq Capital Market upon the commencement of trading on
03-26 04:31
FibroBiologics Completes Onboarding Of Clinical Sites For Phase 1/2 Clinical Trial Evaluating Safety And Efficacy Of CYWC628 For Treatment Of Refractory DFUs
FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases
03-05 21:32
